Doria (risperidone extended release) / ROVI Pharmaceuticals Laboratories  >>  Phase 3
Welcome,         Profile    Billing    Logout  

2 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Doria (risperidone extended release) / ROVI Pharmaceuticals Laboratories
PRISMA-3, NCT03160521: Study to Evaluate the Efficacy and Safety of Risperidone in Situ Microparticle (ISM)® in Patients With Acute Schizophrenia

Checkmark Data from PRISMA-3 trial in schizophrenia
Jul 2019 - Jul 2019: Data from PRISMA-3 trial in schizophrenia
Completed
3
438
US, RoW
Risperidone ISM 75 mg, Risperidone ISM, Risperidone ISM 100 mg, Placebo of Risperidone ISM, PLACEBO
Rovi Pharmaceuticals Laboratories
Acute Schizophrenia
12/18
12/18
PRISMA-3_OLE, NCT03870880: Study to Evaluate the Efficacy and Safety of Risperidone ISM® in Patients With Acute Schizophrenia: Open Label Extension

Completed
3
215
US, RoW
Risperidone ISM 75 mg, Risperidone ISM 100 mg
Rovi Pharmaceuticals Laboratories
Schizophrenia
01/20
01/20

Download Options